Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Final data collection is expected in the first half of 2022 Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab

Related Keywords

Jersey ,Germany ,New York ,United States ,Japan ,New Hampshire ,Israel ,China ,Pennsylvania ,Switzerland ,Malvern ,Ron Aldridge Lina Zhang ,Alan Sandler ,Leigh Labrie ,Ingrid Goldberg ,Asaf Danziger ,Danielle Halstrom Xiaoyu Chen ,Zai Lab Contacts ,Twitter ,Zai Lab ,Oncology At Zai Lab ,Zai Lab Limited ,Exchange Commission ,Head Of Global Development ,Zai Lab Forward ,Tumor Treating Fields ,Greater China ,Global Development ,Tumor Treating Field ,Chief Executive ,Treating Fields ,Tumor Treating ,Annual Report ,Private Securities Litigation Reform Act ,Lab Contacts ,Aldridge Lina Zhang ,Halstrom Xiaoyu Chen ,Novocure ,Nnounce ,Mast ,Patient ,Unrolled ,Hase ,Pilot ,Trial ,Humor ,Reating ,Fields ,Plus ,Chemotherapy ,First ,Line ,Treatment ,Pastric ,Dancer ,